Literature DB >> 9127156

Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome.

L S Onderoğlu1, A Kabukçu.   

Abstract

OBJECTIVE: Our purpose was to determine whether unexplained elevations in maternal serum human chorionic gonadotropin in the second trimester may be associated with adverse pregnancy outcome.
METHOD: Between April 1992 and April 1995, 610 pregnant women undergoing second trimester triple marker screening for Down syndrome who delivered at our institution were evaluated. Eighty-one women with a hCG level greater than 2.0 multiples of the median (MoM) were included in the study group while 481 women with hCG levels < 2.0 MoM served as controls. Pregnancies with fetal chromosomal and structural anomalies and maternal serum alpha-fetoprotein levels greater than 2.0 MoM were excluded from the study. Pregnancy outcomes were obtained from hospital delivery records. Statistical analysis were performed by Student's t-test; odds ratios and 95% confidence intervals were also calculated.
RESULTS: Women with elevated human chorionic gonadotropin levels showed an increased risk for preeclampsia (odds ratio (OR): 5.93, 95% confidence interval (CI): 1.97-15.88), intrauterine growth retardation (OR: 5.34, 95% CI: 2.14-13.34), preterm delivery (OR: 5.66, 95% CI: 3.22-9.98), and preterm premature rupture of membranes (OR: 3.15, 95% CI: 1.23-8.07).
CONCLUSION: Unexplained elevation of human chorionic gonadotropin in the second trimester appears to be associated with adverse pregnancy outcome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127156     DOI: 10.1016/s0020-7292(96)02830-5

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  7 in total

Review 1.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Association Between Serum Markers Used in the Routine Prenatal Screening with Pregnancy Outcomes: A Cohort Study.

Authors:  Zohreh Alizadeh-Dibazari; Zahra Alizadeh-Ghodsi; Azita Fathnezhad-Kazemi
Journal:  J Obstet Gynaecol India       Date:  2021-08-06

Review 3.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.

Authors:  Rachel K Morris; Jeltsje S Cnossen; Marloes Langejans; Stephen C Robson; Jos Kleijnen; Gerben Ter Riet; Ben W Mol; Joris A M van der Post; Khalid S Khan
Journal:  BMC Pregnancy Childbirth       Date:  2008-08-04       Impact factor: 3.007

4.  Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction.

Authors:  Ryo Kiyokoba; Takeshi Uchiumi; Mikako Yagi; Takahiro Toshima; Shigehiro Tsukahara; Yasuyuki Fujita; Kiyoko Kato; Dongchon Kang
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

5.  The Effect of Serum β-Human Chorionic Gonadotropin on Pregnancy Complications and Adverse Pregnancy Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Ju Huang; Yuying Liu; Hua Yang; Yuanfang Xu; Wei Lv
Journal:  Comput Math Methods Med       Date:  2022-09-09       Impact factor: 2.809

Review 6.  The Prenatal Hormone Milieu in Autism Spectrum Disorder.

Authors:  Whitney Worsham; Susan Dalton; Deborah A Bilder
Journal:  Front Psychiatry       Date:  2021-07-01       Impact factor: 4.157

7.  Do triple test results predict risk for neonatal hyperbilirubinemia?

Authors:  Hale Goksever Celik; Engin Celik; Gokhan Yildirim; Merih Cetinkaya
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.